Burlington, MA, United States of America

Arnab De

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Arnab De: Innovator in Anti-RSV Antibodies

Introduction

Arnab De is a notable inventor based in Burlington, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of anti-respiratory syncytial virus (RSV) antibodies. His work is crucial in addressing viral infections that affect infants and young children.

Latest Patents

Arnab De holds a patent titled "Formulations of Anti-RSV Antibodies and Methods of Use Thereof." This patent represents his innovative approach to combating RSV, which is a leading cause of respiratory illness in young children. He has 1 patent to his name, showcasing his commitment to advancing medical science.

Career Highlights

Arnab De is currently employed at Merck Sharp & Dohme LLC, a global leader in pharmaceuticals. His role at the company allows him to work on cutting-edge research and development projects that aim to improve health outcomes for patients worldwide. His expertise in antibody formulations is a valuable asset to the team.

Collaborations

Arnab collaborates with various professionals in his field, including his coworker Venus Hashemi. Together, they contribute to the innovative research environment at Merck Sharp & Dohme LLC, focusing on developing effective treatments for viral infections.

Conclusion

Arnab De is a dedicated inventor whose work in anti-RSV antibodies is making a significant impact in the medical field. His contributions through his patent and collaboration with colleagues highlight the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…